top of page
The Professional Network for Healthcare Experts
CHMP backs Trodelvy plus Keytruda for first-line PD-L1-positive metastatic breast cancer
If authorised, the combination would add an antibody-drug conjugate-based first-line option for eligible European patients with unresectable locally advanced or metastatic triple-negative breast cancer.
nuaxia
Jul 272 min read
FDA Approves MSD’s Keytruda Combinations with Padcev for Muscle-Invasive Bladder Cancer
The approvals expand the use of Keytruda and Keytruda Qlex alongside Padcev into the perioperative treatment setting for adults with muscle-invasive bladder cancer.
nuaxia
Jul 134 min read
FDA backs Merck’s dual-pronged push in kidney cancer with Welireg–Keytruda combo approval
The US Food and Drug Administration (FDA) has approved a combination regimen of Merck & Co.’s Keytruda (pembrolizumab) and Welireg (belzutifan).
nuaxia
Jun 152 min read
MSD Secures European Approval for Keytruda Combination Therapy in Ovarian Cancer
Keytruda now approved across EU for PD-L1-positive platinum-resistant ovarian, fallopian tube, and primary peritoneal carcinoma.
nuaxia
Apr 81 min read
bottom of page